Erratum: Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy (Scientific Reports (2015) 5 (10353) DOI: 10.1038/srep10353));Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cui, Guozhen ^a,b   Shan, Luchen ^c,d   Guo, Lin ^c   Chu, Ivan Keung ^e   Li, Guohui ^e   Quan, Quan ^c   Zhao, Yun ^e   Chong, Cheong Meng ^a   Zhang, Zaijun ^c   Yu, Pei ^c   Hoi, Maggie Pui Man ^a   Sun, Yewei ^c   Wang, Yuqiang ^c   Lee, Simon Ming Yuen ^a  

^a University of Macau   (Macao)

^b ZUNYI MEDICAL UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3,4-DIHYDROXYPHENYLLACTIC ACID; ACTIN BINDING PROTEIN; ADENOSINE DIPHOSPHATE; CELL ADHESION MOLECULE; CHLORIDE; FERRIC CHLORIDE; FERRIC ION; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEME OXYGENASE 1; LACTIC ACID DERIVATIVE; PADGEM PROTEIN; PDIA3 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN BINDING; PROTEIN DISULFIDE ISOMERASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEOMICS; RAT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VENOUS THROMBOSIS;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PLATELETS; CELL ADHESION MOLECULES; CHLORIDES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; HUMANS; LACTATES; MICROFILAMENT PROTEINS; MODELS, BIOLOGICAL; P-SELECTIN; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; PROTEIN DISULFIDE-ISOMERASES; PROTEOMICS; RATS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84930619921     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13509     Document Type: Erratum

References (47)

1. Roger V. L. et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125, e2-e220 (2012).
2. Martinelli I., Bucciarelli P., & Mannucci P. M. Thrombotic risk factors: basic pathophysiology. Crit Care Med 38, S3-9 (2010).
3. Hansson G. K., & Klareskog L. Pulling down the plug on atherosclerosis: cooling down the inflammasome. Nat Med 17, 790-791 (2011).
4. Investigators AWGotA et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
5. Investigators A et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360, 2066-2078 (2009).
6. Cui Q et al. Design, Synthesis, and Preliminary Cardioprotective Effect Evaluation of Danshensu Derivatives. Chem Biol Drug des 84, 282-291 (2014).
7. Cui G. et al. A novel Danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways. Int J Cardiol 168, 1349-1359 (2013).
8. Tian P. Convergence: Where West meets East. Nature 480, S84-86 (2011).
9. Jia Y., Huang F., Zhang S., & Leung S. W. Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris?. A systematic review of randomized controlled trials. Int J Cardiol 157, 330-340 (2012).
10. Cheng T. O. Cardiovascular effects of Danshen. Int J Cardiol 121, 9-22 (2007).
11. Zhou L. M., Zuo Z., & Chow M. S. S. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45, 1345-1359 (2005).
12. Essex D. W. Redox control of platelet function. Antioxid Redox Signal 11, 1191-1225 (2009).
13. Furie B., Flaumenhaft R. Thiol isomerases in thrombus formation. Circ Res 114, 1162-1173 (2014).
14. Cho J. Protein disulfide isomerase in thrombosis and vascular inflammation. J Thromb Haemost 11, 2084-2091 (2013).
15. Cho J., Furie B. C., Coughlin S. R., & Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 118, 1123-1131 (2008).
16. Kim K. et al. Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood 122, 1052-1061 (2013).
17. Reinhardt C. et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 118, 1110-1122 (2008).
18. Holbrook L. M. et al. The platelet-surface thiol isomerase enzyme ERp57 modulates platelet function. J Thromb Haemost 10, 278-288 (2012).
19. Wu Y. et al. The disulfide isomerase ERp57 mediates platelet aggregation, hemostasis, and thrombosis. Blood 119, 1737-1746 (2012).
20. Wang L. et al. Platelet-derived ERp57 mediates platelet incorporation into a growing thrombus by regulation of the alphaIIbbeta3 integrin. Blood 122, 3642-3650 (2013).
21. Ferrari D. M., Soling HD. The protein disulphide-isomerase family: unravelling a string of folds. Biochem J 339 (Pt 1), 1-10 (1999).
22. Ravanat C. et al. GPV is a marker of in vivo platelet activation-study in a rat thrombosis model. Thromb Haemost 83, 327-333 (2000).
23. Moog S. et al. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood 98, 1038-1046 (2001).
24. Freedman J. E. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 28, s11-16 (2008).
25. Corazzari M. et al. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer 96, 1062-1071 (2007).
26. Laurindo F. R., Pescatore L. A., Fernandes Dde C. Protein disulfide isomerase in redox cell signaling and homeostasis. Free Radic Biol Med 52, 1954-1969 (2012).
27. Massberg S. et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 103, 136-142 (2004).
28. Horstrup K. et al. Phosphorylation of Focal Adhesion Vasodilator-Stimulated Phosphoprotein at Ser157 in Intact Human Platelets Correlates with Fibrinogen Receptor Inhibition. Eur J Biochem 225, 21-27 (1994).
29. Peng L. et al. Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis. Antioxid Redox Signal 6, 729-735 (2004).
30. Bertling A. et al. Staphylococcal extracellular adherence protein induces platelet activation by stimulation of thiol isomerases. Arterioscler Thromb Vasc Biol 32, 1979-1990 (2012).
31. Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
32. Mor-Cohen R., Rosenberg N., Averbukh Y., Seligsohn U., & Lahav J. Disulfide bond exchanges in integrins alphaIIbbeta3 and alphavbeta3 are required for activation and post-ligation signaling during clot retraction. Thromb Res 133, 826-836 (2014).
33. Butera D., Cook K. M., Chiu J., Wong J. W., & Hogg P. J. Control of blood proteins by functional disulfide bonds. Blood 123, 2000-2007 (2014).
34. Wu M. L., Ho Y. C., & Yet S. F. A central role of heme oxygenase-1 in cardiovascular protection. Antioxid Redox Signal 15, 1835-1846 (2011).
35. Cheng H. J. et al. Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol Immunol 47, 398-406 (2009).
36. Immenschuh S. et al. Antibodies against dengue virus nonstructural protein-1 induce heme oxygenase-1 via a redox-dependent pathway in human endothelial cells. Free Radic Biol Med 54, 85-92 (2013).
37. Jin R. C. et al. Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. Circulation 123, 1963-1973 (2011).
38. Li S. et al. Pharmacokinetic and Metabolic Studies of ADTM: A Novel Danshensu Derivative Confers Cardioprotection by HPLC-UV and LC-MS/MS. J Chromatogr Sci, doi: 10.1093 (2015).
39. Jasuja R. et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 122, 2104-2113 (2012).
40. Kennedy D. R. et al. Development Of Second Generation Thiol Isomerase Inhibitors To Prevent Thrombus Formation. Blood 122, 926-926 (2013).
41. Flaumenhaft R. Protein disulfide isomerase as an antithrombotic target. Trends Cardiovasc Med 23, 264-268 (2013).
42. Loving G. S., Caravan P. Activation and retention: a magnetic resonance probe for the detection of acute thrombosis. Angew Chem Int Ed Engl 53, 1140-1143 (2014).
43. Zhou J. et al. The disulfide isomerase ERp57 is required for fibrin deposition in vivo. J Thromb Haemost 12, 1890-1897 (2014).
44. Liu C. X. et al. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol 8, 486-493 (2012).
45. Antoniou A. N. et al. The oxidoreductase ERp57 efficiently reduces partially folded in preference to fully folded MHC class I molecules. EMBO J 21, 2655-2663 (2002).
46. Yang S. et al. Pellino3 targets RIP1 and regulates the pro-Apoptotic effects of TNF-Alpha. Nat Commun 4, 2583 (2013).
47. Hennan J. K. et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 6, 1558-1564 (2008).